Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän

Detection of Circulating … - Göteborgs universitet Till startsida
Till innehåll Läs mer om hur kakor används på gu.se



OBS! Vill du ha svar, ange e-post eller telefonnummer!

Detection of Circulating Tumor DNA in Plasma: A Potential Biomarker for Esophageal Adenocarcinoma

Artikel i vetenskaplig tidskrift
Författare M. Egyud
M. Tejani
A. Pennathur
J. Luketich
P. Sridhar
E. Yamada
Anders Ståhlberg
Stefan Filges
P. Krzyzanowski
J. Jackson
I. Kalatskaya
W. Jiao
G. Nielsen
Z. R. Zhou
V. Litle
L. Stein
T. Godfrey
Publicerad i Annals of Thoracic Surgery
Volym 108
Nummer/häfte 2
Sidor 343-349
ISSN 0003-4975
Publiceringsår 2019
Publicerad vid Sahlgrenska Cancer Center
Sidor 343-349
Språk en
Länkar dx.doi.org/10.1016/j.athoracsur.201...
Ämnesord cancer, recurrence, mutations, epidemiology, diagnosis, patterns, survival, monitor, exome, Cardiovascular System & Cardiology, Respiratory System, Surgery
Ämneskategorier Cancer och onkologi


Background. Recent literature has demonstrated the potential of "liquid biopsy" and detection of circulating tumor (ct)DNA as a cancer biomarker. However, to date there is a lack of data specific to esophageal adenocarcinoma (EAC). This study was conducted to determine how detection and quantification of ctDNA changes with disease burden in patients with EAC and evaluate its potential as a biomarker in this population. Methods. Blood samples were obtained from patients with stage I to IV EAC. Longitudinal blood samples were collected from a subset of patients. Imaging studies and pathology reports were reviewed to determine disease course. Tumor samples were sequenced to identify mutations. Mutations in plasma DNA were detected using custom, barcoded, patient-specific sequencing libraries. Mutations in plasma were quantified, and associations with disease stage and response to therapy were explored. Results. Plasma samples from a final cohort of 38 patients were evaluated. Baseline plasma samples were ctDNA positive for 18 patients (47%) overall, with tumor allele frequencies ranging from 0.05% to 5.30%. Detection frequency of ctDNA and quantity of ctDNA increased with stage. Data from longitudinal samples indicate that ctDNA levels correlate with and precede evidence of response to therapy or recurrence. Conclusions. ctDNA can be detected in plasma of EAC patients and correlates with disease burden. Detection of ctDNA in early-stage EAC is challenging and may limit diagnostic applications. However, our data demonstrate the potential of ctDNA as a dynamic biomarker to monitor treatment response and disease recurrence in patients with EAC. (C) 2019 by The Society of Thoracic Surgeons

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?